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Introduction
Despite the proliferation of contemporary conflicts, the emergence of antimicrobial resistance (AMR) in settings of war and distressed migration has been neglected. This has been of particular concern in Syria where the protracted and increasingly destructive conflict has also been a driver of large-scale population movements both regionally and in Europe. Since 2012, the conflict has become the leading cause of death and injury in Syria. In the absence of accurate recent figures, it is estimated, as of the end of 2015, that 470 000 have been killed and 1.9 million injured (Syrian Center for Policy Research, 2018) . With high rates of injury, the potential for infection is exacerbated by the crowded and often unsanitary conditions in health facilities, combined with the nature of injuries produced by heavy weaponry.
The destruction of health facilities, the exodus or death of healthcare workers, and the increasing fragmentation of Syria's health system have all contributed to the myriad of challenges in addressing AMR (Fouad et al., 2017) . By April 2017, only 56 out of 111 public hospitals were still offering services (WHO, 2018) , while it has been estimated that over 70% of all health professionals have left the country since the conflict began. Of the 6.4 million internally displaced persons (IDPs) estimated by the United Nations Office for the Coordination of Humanitarian Affairs (OCHA), more than one million live in unhygienic conditions in overcrowded camps and collective shelters, at increased risk of typhoid, hepatitis, cholera, polio, and cutaneous leishmaniasis, among other infectious diseases (Ismail et al., 2016) .
Under conditions of conflict, many of the safeguards against AMR are broken and drivers are accentuated; these include damaged health and sanitation infrastructure, disrupted medical supplies, the exodus of expert and trained health professionals, and increasing exposure in compromised healthcare settings. War further disrupts the political and regulatory bodies that often lead, monitor, and enforce policies that tackle the drivers of AMR. This first part of a two-part series presents a review and analysis of the literature on what is known about AMR in the Syrian conflict. The second part explores the pre-existing drivers of AMR in Syria and those that have occurred since the onset of conflict; recommendations on how these can be addressed are also made.
Evidence of AMR in the Syrian context
Rigorous studies addressing microbiology or AMR in Syria, either before or since the onset of the conflict in March 2011, are scarce. Published studies have often been from a single centre and have presented limited data of variable quality. Functioning laboratories are restricted to major cities such as Damascus, Aleppo, and Lattakia, mainly in government-controlled areas (GCAs). Whether private or hospital-based, all laboratories close between Thursday afternoon and Sunday morning. As there is no on-call service, laboratory services are unavailable for 2.5 days each week. These laboratories are inaccessible to health workers serving the outskirts of these cities and rural areas in GCAs, in addition to the estimated 10 million people living in nongovernment-controlled areas (NGCAs), served by six laboratories (verbal communication) (Plate 1 ).
There are two parallel systems of surveillance. From Damascus, the Syrian Arab Republic Ministry of Health with the support of the World Health Organization (WHO) collects reports of notifiable diseases through the Early Warning and Response System (EWARS), but without laboratory testing of samples or contact tracing. Operating from Gaziantep in southern Turkey, the Early Warning and Response Network (EWARN) system is hampered by the paucity of laboratory services and the absence of local referral laboratories for verification and typing. Data from these systems may not be reliable in this context, nor generalizable across the country (Ismail et al., 2016; Sparrow et al., 2016) . Neither system requires reporting on AMR, nosocomial infections, or response to therapy. Both systems are hampered by limited surveillance in governorates under the control of ISIS (Raqqa and Deir Ezzor) and the lack of quality control services and access to accredited referral laboratories. In GCAs this requires shipping of samples to Egypt; in NGCAs this requires cross-border transport to Turkey or Jordan, subject to permission from the relevant ministry of health. Both circumstances are challenging given the insecurity, difficulty in transporting specimens under controlled temperature conditions, and restricted access across borders.
A review of the scientific literature describing AMR amongst Syrians who remain in Syria and those who are refugees either in the region (Jordan, Lebanon, Turkey) or in Europe was performed to accurately describe the current literature on AMR in the Syrian conflict. The search methods are given in the Appendix A. Table 1 summarizes studies addressing AMR before and after the onset of the conflict, including all published articles relating to refugees or Syrians inside Syria.
Evidence of AMR in the Syrian context: pre-conflict
Before the conflict, several reports suggested the widespread availability of antibiotics through pharmacies without safeguards and/or poor knowledge amongst recipients of the risks associated with injudicious antibiotic use (Barah and Gonçalves, 2010) . Anecdotally, extensive antibiotic overuse and antimicrobial failure were common. Limited evidence documenting the existence and prevalence of AMR was found in the perusal of the scientific literature. Studies identified were notable for their small size, inconsistent reporting, and questionable methodology, compromising the potential to identify trends or draw conclusions concerning AMR. Most studies were reported from the cities of Damascus and Aleppo, limiting generalization across and to other governorates.
Seven studies describing antibiotic susceptibility amongst different isolates were found ( Table 1 ). The majority focused on specific bacteria including Acinetobacter baumannii, Streptococcus pneumoniae, and Brucella melitensis (Hamzeh et al., 2012; Turkmani et al., 2006; Obeid and Obeid, 2005) . Hamzeh and colleagues reported high levels of AMR in 260 unique patients with A. baumannii infections from Aleppo in 2008 -2011 (Hamzeh et al., 2012 . Resistance to imipenem and meropenem (carbapenems) was reported at 66%, to ciprofloxacin (fluoroquinolone) 81%, piperacillin-tazobactam (penicillin-beta-lactamase) 87%, amikacin (aminoglycoside) 78%, and to co-trimoxazole (sulfonamide) 74%. Resistance to third-and fourth-generation cephalosporins was also high, with ceftazidime resistance reported at 80.6% and cefepime at 84.7%. Colistin remained active with only 7% reported resistance. The main drawback of this study was the use of an automated system for species identification, bearing in mind that these systems are unable to precisely distinguish isolates from the A. baumannii-Acinetobacter calcoaceticus complex to the species level. Keddo et al. reported that 25% of Klebsiella pneumoniae isolates amongst children with recurrent tonsillitis were carbapenem-resistant (Keddo and Al-Omari, 2012) . With regards to Gram-positive isolates, the most recent study found was conducted in 2005: Obeid and colleagues reported high rates of resistance to penicillin (64%) and trimethoprim-sulfamethoxazole (48%) in 25 isolates of S. pneumoniae from cerebrospinal fluid samples, but found no resistance to cephalosporins (including cefotaxime and ceftriaxone), often used as first-line therapy for bacterial meningitis (Obeid and Obeid, 2005) .
Although these reports describe small numbers, they raise concern regarding the high rates of AMR reported. The high proportion of carbapenem-resistant Gram-negatives is alarming given that carbapenems are used as broad-spectrum or salvage therapy following failure of empiric therapy. The percentage of penicillin-resistant S. pneumoniae is troubling, as overuse of antibiotics in the treatment of viral illness is a driver of penicillin resistance in this isolate.
Evidence of AMR in the Syrian context: since the onset of the conflict in 2011
Since the first use of armed force and subsequent expansion of violence, data on the availability and efficacy of antimicrobial therapy within Syria have become increasingly limited. Six studies from inside Syria since late 2011 have reported concerns over the increasing burden ofresistant Gram-negative infections and methicillin-resistant Staphylococcus aureus (MRSA), four of these being focused on Aleppo (Alheib et al., 2015; Mahfoud et al., 2015; Al-Assil et al., 2013; Tabana et al., 2015) . It is notable that few datasets from within Syria have reported on war-related injuries and their infectious complications; this is likely driven by several factors including political sensitivities and the overwhelmed health systems.
Studies of resistance from inside Syria on specific isolates have reported high levels of AMR. Zain and colleagues examined 236 Escherichia coli isolates and found 26% of these to be extendedspectrum beta-lactamase (ESBL) producers (Baaity et al., 2017) . Alheib and colleagues examined 123 ESBL-producing E. coli and K. pneumoniae specimens in 2015 and found 66% of these isolates to be phenotypically resistant to ciprofloxacin (Alheib et al., 2015 ). Mahfoud and colleagues tested 177 Pseudomonas aeruginosa urinary and lower respiratory isolates from patients in three intensive care units in Aleppo and showed significant resistance to common anti-pseudomonal agents (piperacillin-tazobactam: 46%; meropenem: 41%; ceftazidime 73%) with colistin as the most reliable antibiotic (11% resistance) (Mahfoud et al., 2015) . Al-Assil reviewed 104 patients with positive urine samples to understand the risk factors for the development of ESBL infections and isolated ESBL E. coli in 52% of cases (Al-Assil et al., 2013) . Co-resistance to other antibiotics was found in 82% of cases. Risk factors identified as increasing the risk of ESBL acquisition in that study included older age (>52 years), hospitalization, urinary catheterization, and previous exposure to third-generation cephalosporins or quinolone antibiotics (Al-Assil et al., 2013) .
Of the few large regional studies, a recent retrospective study in Lebanon analysing 55 594 Gram-negative isolates between 2011 and 2013 reported ESBL rates amongst E. coli and Klebsiella spp of 32.3% and 29.2%, respectively (Chamoun et al., 2016) . Lebanon and Jordan, countries neighbouring Syria and hosting an estimated total of 1.7 million refugees, both reported the emergence of multidrug-resistant (MDR) Gram-negative infections complicating war-related injuries (Teicher et al., 2014; Abbara et al., 2017; Rafei Plate 1. This is a map of Syria which shows the location of the major cities, Damascus, Lattakia and Aleppo where the main functioning laboratories remain. (Teicher et al., 2014) . A cohort of 61 young men (median age 26 years) presented to the hospital with clinically infected chronic war wounds (injury to presentation time median 5 months, interquartile range 1.2-8.1 months). Gunshot (31 patients) and explosion-related (20 patients) wounds were the most common injuries. Of the 61 patients, 45 had at least one positive culture, with 69% (31/45) of isolates being MDR. Although numbers were small, high rates of carbapenem-resistant A. baumannii (80%; 4/5), ESBL-producing E. coli (62%; 5/8), and MRSA (41%; 7/17) were isolated. Similar rates of MDR organisms have been reported related to war injuries (Teicher et al., 2014; Abbara et al., 2017) , and refugees have been reported to have significantly higher rates of carbapenem-resistant A. baumannii (Rafei et al., 2014) . No data are available from Turkey, which hosts nearly three million Syrian refugees. A more robust evidence base of AMR and the Syrian refugee crisis has come from an increasing number of reports on MDR organism carriage in refugees admitted into European hospitals. Syrian refugee patients screened in Europe have shown higher rates of carbapenemase-producing Enterobacteriaceae (CPEs) compared with local populations (Kassem et al., 2017; Angeletti et al., 2016; Ravensbergen et al., 2016; Reinheimer et al., 2016; Heudorf et al., 2016; Tenenbaum et al., 2016; Heydari et al., 2015) . Estimates of MDR carriage within paediatric and adult populations in these studies range from 33% to 83%, with high rates of New Delhi metallo-beta-lactamase (NDM)-producing carbapenem-resistant Enterobacteriaceae (CRE), A. baumannii, and ESBL-producing Enterobacteriaceae (Rafei et al., 2014; Kassem et al., 2017; Angeletti et al., 2016; Ravensbergen et al., 2016; Reinheimer et al., 2016; Heudorf et al., 2016; Tenenbaum et al., 2016) . This is significantly greater than the background carriage rates of the local populations such as in Germany, where colonization with MDR Gram-negatives was identified in 60.8% of a refugee population (of whom 18.6% were Syrian) screened on admission to hospital versus 16.8% in the general population (Ravensbergen et al., 2016) .
Comparative data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) showed rates of resistance for seven specific pathogens in 2015.
28 Penicillin non-susceptibility in S. pneumoniae ranged from 0.6% in Belgium to 39% in Romania. Carbapenem resistance was 0.1%, 8.1%, and 17.8% in E. coli, K. pneumoniae, and P. aeruginosa, respectively, with the highest rate of 93.5% seen in Acinetobacter sp in Greece. Polymyxin resistance was 0.8%, 4%, and 8.8% in P. aeruginosa, Acinetobacter sp, and K. pneumoniae, respectively. Most K. pneumoniae isolates with combined polymyxin and carbapenem resistance were reported from Greece and Italy. MRSA rates ranged from 0% in Iceland to 57% in Romania.
Conclusions
This review of evidence of AMR inside Syria and in countries hosting Syrian refugees demonstrates a paucity of rigorous studies describing this increasingly important phenomenon. Before the conflict, published studies inside Syria were often from single centres and presented limited data of variable quality. Since the onset of the conflict, no studies have described the prevalence of AMR in those with injuries within Syria. However, evidence from neighbouring countries suggests that this is an increasing phenomenon. It is important to address this research and reporting Tenenbaum et al. (2016) gap, as defining the current extent of AMR among Syrians will help to inform interventions that address the drivers of AMR in this population. This is particularly relevant given the population movements that have resulted from the conflict and the likelihood of ongoing challenges in addressing this issue which is of global importance. However, there are barriers to filling this evidence gap due to a combination of factors relating to the complex humanitarian situation inside Syria and the overwhelmed health systems in neighbouring countries. Collaboration and innovations are required to address this issue, which is of global importance. The second part of this two-part series addresses the drivers of AMR before and after the onset of conflict and makes recommendations as to how these can be addressed.
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